Literature DB >> 12757073

Evaluation of attitude, risk behavior and expectations among Thai participants in Phase I/II HIV/AIDS vaccine trials.

Wirach Maek-A-Nantawat1, Punnee Pitisuttithum, Benjaluck Phonrat, Valai Bussaratid, Supa Naksrisook, Wantanee Peonim, Narumon Thantamnu, Rungrapat Muanaum.   

Abstract

The Understanding of volunteers in vaccine trials about their role as study participants and their voluntary commitment during the study are always one of the important concerns apart from evaluation of safety and efficacy of vaccine trials, especially in HIV prophylactic vaccine trials. The apprehension of indirectly risky behavior encouragement and deviated expectations among volunteers should be of concern. The current prospective cohort study aimed to assess and monitor the changes of risk behaviors, attitude and expectations among 164 volunteers from 2 studies of different prophylactic HIV vaccines, the Chiron HIV Thai E gp 120/MF59 +/- the Chiron HIV SF52 gp120 and Aventis Pasteur Live Recombinant ALVAC HIV (vCP1521) priming with VaxGen gp120B/E (AIDSVAX B/E) boosting. 113 males and 51 females with a mean age (+/- SD) of 28.82 +/- 7.97 years old were enrolled from October 1997 to December 1998 and February 2000 to April 2001. Education and risk reduction counseling were regularly performed at every visit and questionnaires about risk behaviors, knowledge, attitudes, social influences and expectations were asked at baseline, 4 months and 12 months. No change of potentially HIV transmission related risk behavior was observed during the studies. There was a statistically significant decrease of risk sexual practices from the beginning of the trials (42.2% vs 1%, p < 0.0001). While 35.2 per cent from 62.2 per cent of the volunteers at the beginning of the study continued sexual practice with an identified single sexual partner at the end of the study (p < 0.0001). All of the volunteers expressed the beneficial expectations as knowledge gain, social contribution, feelings of having gained merit and self-benefits from health check-ups.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12757073

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  5 in total

1.  Expectation of volunteers towards the vaccine efficacy of the prime-boost HIV vaccine phase III trial during unblinding.

Authors:  Kessuda Khowsroy; Jittima Dhitavat; Yupa Sabmee; Pataramon Laowarakul; Jutarat Wattanakitwichai; Jiraporn Auetian; Kannika Lothong; Roongtip Boondao; Sarawan Maythaarttaphong; Sunee Yaemwong; Jean-Louis Excler; Supachai Rerks-Ngarm; Punnee Pitisuttithum
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-08       Impact factor: 2.205

Review 2.  Socio-behaviour challenges to phase III HIV vaccine trials in Sub-Saharan Africa.

Authors:  Joalida Smit; Keren Middelkoop; Landon Myer; Graham Lindegger; Leslie Swartz; Soraya Seedat; Tim Tucker; Robin Wood; Linda-Gail Bekker; Dan J Stein
Journal:  Afr Health Sci       Date:  2005-09       Impact factor: 0.927

3.  Peruvian Female Sex Workers' Ethical Perspectives on Their Participation in an HPV Vaccine Clinical Trial.

Authors:  Brandon Brown; Mariam Davtyan; Celia B Fisher
Journal:  Ethics Behav       Date:  2014-08-14

4.  A qualitative evaluation of volunteers' experiences in a phase I/II HIV vaccine trial in Tanzania.

Authors:  Edith A M Tarimo; Anna Thorson; Thecla W Kohi; Muhammad Bakari; Eric Sandstrom; Fred Mhalu; Asli Kulane
Journal:  BMC Infect Dis       Date:  2011-10-24       Impact factor: 3.090

5.  Experiences of social harm and changes in sexual practices among volunteers who had completed a phase I/II HIV vaccine trial employing HIV-1 DNA priming and HIV-1 MVA boosting in Dar es Salaam, Tanzania.

Authors:  Edith A M Tarimo; Patricia Munseri; Said Aboud; Muhammad Bakari; Fred Mhalu; Eric Sandstrom
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.